Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease.
Identifieur interne : 001276 ( PubMed/Checkpoint ); précédent : 001275; suivant : 001277Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease.
Auteurs : C. Thalamas [France] ; A. Taylor ; C. Brefel-Courbon ; S. Eagle ; K. Fitzpatrick ; O. RascolSource :
- European journal of clinical pharmacology [ 0031-6970 ] ; 1999.
English descriptors
- KwdEn :
- Administration, Oral, Aged, Antiparkinson Agents (adverse effects), Antiparkinson Agents (pharmacokinetics), Antiparkinson Agents (therapeutic use), Cytochrome P-450 CYP1A2 (metabolism), Dopamine Agonists (adverse effects), Dopamine Agonists (pharmacokinetics), Dopamine Agonists (therapeutic use), Drug Interactions, Female, Humans, Indoles (adverse effects), Indoles (pharmacokinetics), Indoles (therapeutic use), Injections, Intravenous, Male, Middle Aged, Parkinson Disease (drug therapy), Theophylline (adverse effects), Theophylline (pharmacology), Theophylline (therapeutic use), Vasodilator Agents (adverse effects), Vasodilator Agents (pharmacology), Vasodilator Agents (therapeutic use).
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Dopamine Agonists, Indoles, Theophylline, Vasodilator Agents.
- chemical , metabolism : Cytochrome P-450 CYP1A2.
- chemical , pharmacokinetics : Antiparkinson Agents, Dopamine Agonists, Indoles.
- chemical , pharmacology : Theophylline, Vasodilator Agents.
- chemical , therapeutic use : Antiparkinson Agents, Dopamine Agonists, Indoles, Theophylline, Vasodilator Agents.
- drug therapy : Parkinson Disease.
- Administration, Oral, Aged, Drug Interactions, Female, Humans, Injections, Intravenous, Male, Middle Aged.
Abstract
Ropinirole and theophylline have the potential to interact, because they use the same hepatic cytochrome P450 (CYP1A2) as their major metabolic pathway. The present study investigated the effect of steady-state oral theophylline on the pharmacokinetics of ropinirole at steady state and the effect of steady-state ropinirole on the pharmacokinetics of a single intravenous (i.v.) dose of theophylline, both in patients with idiopathic Parkinson's disease (PD).
PubMed: 10424323
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:10424323Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease.</title><author><name sortKey="Thalamas, C" sort="Thalamas, C" uniqKey="Thalamas C" first="C" last="Thalamas">C. Thalamas</name><affiliation wicri:level="3"><nlm:affiliation>Clinical Investigation Centre, University Hospital-INSERM, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Clinical Investigation Centre, University Hospital-INSERM, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Taylor, A" sort="Taylor, A" uniqKey="Taylor A" first="A" last="Taylor">A. Taylor</name></author><author><name sortKey="Brefel Courbon, C" sort="Brefel Courbon, C" uniqKey="Brefel Courbon C" first="C" last="Brefel-Courbon">C. Brefel-Courbon</name></author><author><name sortKey="Eagle, S" sort="Eagle, S" uniqKey="Eagle S" first="S" last="Eagle">S. Eagle</name></author><author><name sortKey="Fitzpatrick, K" sort="Fitzpatrick, K" uniqKey="Fitzpatrick K" first="K" last="Fitzpatrick">K. Fitzpatrick</name></author><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1999">1999</date><idno type="RBID">pubmed:10424323</idno><idno type="pmid">10424323</idno><idno type="wicri:Area/PubMed/Corpus">001401</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001401</idno><idno type="wicri:Area/PubMed/Curation">001360</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001360</idno><idno type="wicri:Area/PubMed/Checkpoint">001360</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001360</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease.</title><author><name sortKey="Thalamas, C" sort="Thalamas, C" uniqKey="Thalamas C" first="C" last="Thalamas">C. Thalamas</name><affiliation wicri:level="3"><nlm:affiliation>Clinical Investigation Centre, University Hospital-INSERM, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Clinical Investigation Centre, University Hospital-INSERM, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Taylor, A" sort="Taylor, A" uniqKey="Taylor A" first="A" last="Taylor">A. Taylor</name></author><author><name sortKey="Brefel Courbon, C" sort="Brefel Courbon, C" uniqKey="Brefel Courbon C" first="C" last="Brefel-Courbon">C. Brefel-Courbon</name></author><author><name sortKey="Eagle, S" sort="Eagle, S" uniqKey="Eagle S" first="S" last="Eagle">S. Eagle</name></author><author><name sortKey="Fitzpatrick, K" sort="Fitzpatrick, K" uniqKey="Fitzpatrick K" first="K" last="Fitzpatrick">K. Fitzpatrick</name></author><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name></author></analytic><series><title level="j">European journal of clinical pharmacology</title><idno type="ISSN">0031-6970</idno><imprint><date when="1999" type="published">1999</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term><term>Aged</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (pharmacokinetics)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Cytochrome P-450 CYP1A2 (metabolism)</term><term>Dopamine Agonists (adverse effects)</term><term>Dopamine Agonists (pharmacokinetics)</term><term>Dopamine Agonists (therapeutic use)</term><term>Drug Interactions</term><term>Female</term><term>Humans</term><term>Indoles (adverse effects)</term><term>Indoles (pharmacokinetics)</term><term>Indoles (therapeutic use)</term><term>Injections, Intravenous</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Theophylline (adverse effects)</term><term>Theophylline (pharmacology)</term><term>Theophylline (therapeutic use)</term><term>Vasodilator Agents (adverse effects)</term><term>Vasodilator Agents (pharmacology)</term><term>Vasodilator Agents (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agonists</term><term>Indoles</term><term>Theophylline</term><term>Vasodilator Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Cytochrome P-450 CYP1A2</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agonists</term><term>Indoles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Theophylline</term><term>Vasodilator Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agonists</term><term>Indoles</term><term>Theophylline</term><term>Vasodilator Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Aged</term><term>Drug Interactions</term><term>Female</term><term>Humans</term><term>Injections, Intravenous</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Ropinirole and theophylline have the potential to interact, because they use the same hepatic cytochrome P450 (CYP1A2) as their major metabolic pathway. The present study investigated the effect of steady-state oral theophylline on the pharmacokinetics of ropinirole at steady state and the effect of steady-state ropinirole on the pharmacokinetics of a single intravenous (i.v.) dose of theophylline, both in patients with idiopathic Parkinson's disease (PD).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10424323</PMID><DateCreated><Year>1999</Year><Month>09</Month><Day>08</Day></DateCreated><DateCompleted><Year>1999</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0031-6970</ISSN><JournalIssue CitedMedium="Print"><Volume>55</Volume><Issue>4</Issue><PubDate><Year>1999</Year><Month>Jun</Month></PubDate></JournalIssue><Title>European journal of clinical pharmacology</Title><ISOAbbreviation>Eur. J. Clin. Pharmacol.</ISOAbbreviation></Journal><ArticleTitle>Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>299-303</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Ropinirole and theophylline have the potential to interact, because they use the same hepatic cytochrome P450 (CYP1A2) as their major metabolic pathway. The present study investigated the effect of steady-state oral theophylline on the pharmacokinetics of ropinirole at steady state and the effect of steady-state ropinirole on the pharmacokinetics of a single intravenous (i.v.) dose of theophylline, both in patients with idiopathic Parkinson's disease (PD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Pharmacokinetic parameters (AUC and Cmax) for i.v. theophylline were compared before and after a 4-week period of oral treatment with ropinirole (2 mg t.i.d.) in 12 patients with PD. Patients were then maintained at this dose of ropinirole, and oral theophylline was co-administered at doses of up to 300 mg b.i.d. The parameters AUC, Cmax and tmax for ropinirole were compared before, during and after oral theophylline co-treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Co-administration of ropinirole did not significantly change the pharmacokinetics of i.v. theophylline (mean AUC with and without ropinirole: 68.6 micog x h(-1) x ml(-1) and 70.0 microg x h(-1) x ml(-1), respectively: mean Cmax with and without ropinirole: 11.07 microg x ml(-1) and 11.83 microg x ml(-1), respectively). Similarly, there were no significant changes in ropinirole pharmacokinetics when the drug was co-administered with oral theophylline (mean AUC for ropinirole with and without theophylline: 21.91 ng x h(-1) x ml(-1) and 22.09 ng x h(-1) x ml(-1), respectively; mean Cmax for ropinirole with and without theophylline: 5.65 ng x ml(-1) and 5.54 ng x ml(-1), respectively; median tmax for ropinirole with and without theophylline: 2.0 h and 1.5 h, respectively).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results suggest a lack of significant pharmacokinetic interaction between the two drugs at current therapeutic doses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thalamas</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinical Investigation Centre, University Hospital-INSERM, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Brefel-Courbon</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Eagle</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Fitzpatrick</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Rascol</LastName><ForeName>O</ForeName><Initials>O</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Clin Pharmacol</MedlineTA><NlmUniqueID>1256165</NlmUniqueID><ISSNLinking>0031-6970</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>030PYR8953</RegistryNumber><NameOfSubstance UI="C046649">ropinirole</NameOfSubstance></Chemical><Chemical><RegistryNumber>C137DTR5RG</RegistryNumber><NameOfSubstance UI="D013806">Theophylline</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.14.1</RegistryNumber><NameOfSubstance UI="D019388">Cytochrome P-450 CYP1A2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019388" MajorTopicYN="N">Cytochrome P-450 CYP1A2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007275" MajorTopicYN="N">Injections, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013806" MajorTopicYN="N">Theophylline</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>7</Month><Day>29</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>7</Month><Day>29</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10424323</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Midi-Pyrénées</li><li>Occitanie (région administrative)</li></region><settlement><li>Toulouse</li></settlement></list><tree><noCountry><name sortKey="Brefel Courbon, C" sort="Brefel Courbon, C" uniqKey="Brefel Courbon C" first="C" last="Brefel-Courbon">C. Brefel-Courbon</name><name sortKey="Eagle, S" sort="Eagle, S" uniqKey="Eagle S" first="S" last="Eagle">S. Eagle</name><name sortKey="Fitzpatrick, K" sort="Fitzpatrick, K" uniqKey="Fitzpatrick K" first="K" last="Fitzpatrick">K. Fitzpatrick</name><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name><name sortKey="Taylor, A" sort="Taylor, A" uniqKey="Taylor A" first="A" last="Taylor">A. Taylor</name></noCountry><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Thalamas, C" sort="Thalamas, C" uniqKey="Thalamas C" first="C" last="Thalamas">C. Thalamas</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001276 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001276 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:10424323
|texte= Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:10424323" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |